Breaking News

0 75
Akorn, Inc. AKRX Stock News

Akorn, Inc. (NASDAQ: AKRX) was off to what seemed like it was going to be a rough day in the market today. However, that all changed minutes ago as reports came out that the company was nearing a deal to be taken over. Of course, this led to excitement among investors who pushed the stock skyward. While the stock is still not to the green yet, it’s close, and chances are that it will reach the profit zone relatively soon. As is almost always the case, our partners at Trade Ideas were the first to alert us to the gains on the stock. At the moment (12:47), AKRX is trading at $32.78 per share after a gain of $0.13 per share or 0.40% thus far today.





AKRX Nears Deal To Be Acquired

As mentioned above, Akorn wasn’t doing so hot in the market early on this morning. However, minutes ago, that changed as the stock started to spike. The gains are ultimately the result of news of a coming takeover deal. According to Reuters, Fresenius is near a deal to buy the company. If all goes well, they will be purchasing Akorn at between $33 and $35 per share, bringing the mean value of the potential takeover to more than $4 billion.




At the moment, neither of the companies are willing to provide a statement, as can be expected. Nonetheless, if this takeover does happen, it could result in incredible value being returned to AKRX shareholders.

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on AKRX. In particular, we’re interested in following the potential takeover story to see if the potential deal comes to fruition. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Want The News Faster?

Check out the CNA Finance News Desk to get the scoop before we have the time to write the story!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









[Image Courtesy of Wikimedia]

Rex Energy Corporation REXX Stock News

Rex Energy Corporation (NASDAQ: REXX) is having an incredibly strong day in the market today, and for good reason. The company released realized natural gas sales numbers, exceeding expectations and sparking excitement in the minds of investors. As a result, the stock went skyward, prompting our partners at Trade Ideas to alert us to the movement. At the moment (11:53), REXX is trading at $0.40 per share after a gain of $0.07 per share or 21.21% thus far today.





REXX Q1 Sales Are Promising

As mentioned above, Rex Energy Corporation is having a strong day in the market today after releasing sales figures for the first quarter. Here are the key points from the release…




  • REXX realized natural gas prices improved by 42%. This is before hedging and the figure is based on a comparison between the first quarter of 2017 and the fourth quarter of 2016.
  • The company also said that realized C30+ NGL pricing for the first quarter was 59% of WTI before hedging.
  • Finally, the company completed the drilling of a four-well Macrell pad with average lateral length of 7,660 feet.

In a statement, Tom Stabley, President and CEO at REXX had the following to offer…

Our first quarter 2017 results are the first step in achieving our two-year plan for 2017 and 2018… One of the most important highlights of the quarter was our price realizations, with the strong results underlying the importance of our marketing initiatives and current marketing portfolio. With a full year of Gulf Coast transport and improved differentials in the northeast markets, we expect to see improved realizations throughout the year and will continue to pursue further enhancements to our marketing portfolio to further improve our realizations.”

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on REXX. In particular, we’re interested in following the company through their two-year growth plan as the plan is proving effective at the moment. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Want The News Faster?

Check out the CNA Finance News Desk to get the scoop before we have the time to write the full story!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









[Image Courtesy of Wikimedia]

0 415
CytRx Corporation CYTR Stock News

CytRx Corporation (NASDAQ: CYTR) is having an overwhelmingly strong day in the market today following up on Friday’s gains. The gains are ultimately the result of a coming data release that is leading to excitement among investors. As is almost always the case, our partners at Trade Ideas were the first to alert us to the gains. At the moment (11:00), CYTR is trading at $0.75 per share after a gain of $0.14 per share or 22.97% thus far today.





CYTR To Present Clinical Data At ASCO

As mentioned above, CytRx is having a strong day in the market today, following up on Friday’s gains. At the end of the day, the gains are the result of excitement surrounding a coming data release. The company announced that an abstract describing results from the Phase 3 clinical trial of aldoxorubicin compared to the investigators’ choice treatment in relapsed and refractory soft tissue sarcomas has been selected for an oral presentation at the 2017 Americal Society of Clinical Oncology Annual Meeting. The meeting will take place in Chicago between Jun 2 and June 6, 2017. In a statement, Daniel Levitt, M.D., Ph.D., Chief Operating Officer and Chief Medical Officer at CYTR had the following to offer…




We look forward to presenting the more detailed and updated global Phase 3 results to the medical community at ASCO this year… The Phase 3 trial and the combination trial of aldoxorubicin with ifosfamide continue to build on our prior studies showing the utility of aldoxorubicin as a treatment for patients with STS. These trials, together with our clinical and preclinical studies of aldoxorubicin, will support our planned New Drug Application submission.”

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on CYTR. In particular, we’re interested in both the presentation and the coming New Drug Application with the FDA. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Want The News Faster?

Check out the CNA Finance News Desk to get the scoop before we have the time to write the full story!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









[Image Courtesy of Wikimedia]

0 182
PhaseRX Inc PZRX Stock News

PhaseRX Inc (NASDAQ: PZRX) is having an incredibly strong day in the market today, and for good reason. The company has been awarded Orphan Drug Designation by the EMA. Of course, this led to excitement among investors and ultimately gains in the stock. As is normally the case, our partners at Trade Ideas were the first to alert us to the gains. At the moment (10:46), PZRX is trading at $1.43 per share after a gain of $0.19 per share or 15.28% thus far today.





PZRX Awarded Orphan Drug Designation

As mentioned above, PhaseRx is having a strong time in the market early on this morning, and for good reason. The company has received Orphan Drug Designation from the European Medicines Agency. The designation was provided surrounding modified messenger ribonucleic acid encoding human ornithine transcarbamylase enzyme encapsulated into lipid nanoparticles. While the company hasn’t released a press release surrounding this news quite yet, we are expecting to see one at any time.




Ultimately, the orphan drug designation is overwhelmingly positive news. Not only will this help to speed up the process toward approval, it will also assist PZRX in protecting its intellectual property. All in all, there’s a good reason investors are excited here!

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on PZRX. In particular, we’re looking for a press release surrounding the designation as well as the company’s next steps follow the positive news. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Want The News Faster?

Check out the CNA Finance News Desk to get the scoop before we have the time to release the full story!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 274
Sarepta Therapeutics Inc SRPT Stock News

Sarepta Therapeutics Inc (NASDAQ: SRPT) is having a strong day in the market today after the FDA announced a forthcoming Pediatric Advisory Committee meeting. The meeting led to excitement among investors and sent the stock upward. As is nearly always the case, our partners at Trade Ideas were the first to alert us to the gains. At the moment (10:24), SRPT is trading at $33.14 per share after a gain of $0.53 per share or 1.64% thus far today.





SRPT Gains On Coming FDA Advisory Committee Meeting

As mentioned above, Sarepta Therapeutics is having a strong start to the trading session today after the FDA announced that a Pediatric Advisory Committee meeting is coming soon. In the meeting, the FDA and the Pediatric Advisory Committee will discuss SRP-4045 and SRP-4053. Here’s a quick summary from the FDA release with regard to the SRPT meeting…




The Food and Drug Administration (FDA or Agency) announces a forthcoming public advisory committee meeting of the Pediatric Advisory Committee (PAC) and the Pediatric Ethics Subcommittee (PES). The general function of the committees is to provide advice and make recommendations to the Agency on pediatric ethical issues. The meeting will be open to the public.”

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on SRPT. In particular, we’ll be paying close attention to the advisory committee meeting and what the result of the meeting means for the company. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Want The News Faster?

Check out the CNA Finance News Desk to get the scoop before we have the time to write the full story!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









[Image Courtesy of Wikimedia]

0 128
XOMA Rg XOMA Stock News

XOMA Rg (NASDAQ: XOMA) is having a rough day in the market today, and for good reason. It was announced this morning that Novo Nordisk has sent the company notice with regard to the termination of a license agreement. As a result, fear hit investors, leading to declines in the stock. Of course, our partners at Trade Ideas were the first to alert us to the declines. At the moment (10:04), XOMA is trading at $6.98 per share after a loss of $0.75 per share or 9.65% thus far today.





NVO Terminates License Agreement With XOMA

As mentioned above, XOMA is having a rough day in the market today after news broke that Novo Nordisk has notified the company that it will be terminating a licence agreement with the company. The license will be terminated for strategic and business reasons according to NVO.




This is a big hit to XOMA as it will no longer be expecting potential milestone payments that are payable under this license agreement. As a result, the company expects for potentail milestone payments over the next 36 months to fall to $40 million from $50 million.

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on XOMA. While the cancellation of this license agreement is bad news, it does open the door for the company to seek another partner. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Want The News Faster?

Check out the CNA Finance News Desk to get the scoop before we have the time to write the full story!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









For sidebar:

0 153
PDL BioPharma Inc PDLI Stock News

PDL BioPharma Inc (NASDAQ: PDLI) is having an incredibly strong start to the trading session today, and for good reason. Word is circulating that the company’s dispute with Merck & Co. As a result, investors got excited and sent the stock upward. As is nearly always the case, our partners at Trade Ideas were the first to alert us to the gains. At the moment (9:48), PDLI is trading at $2.09 per share after a gain of $0.07 per share or 3.47% thus far today.





MRK Settles With PDLI

As mentioned above, PDL BioPharma is having a strong day in the market today after news started to surface regarding a settlement between the company and Merck. The settlement surrounded Keytruda skin-cancer treatment. This treatment infringed on PDLI intellectual property. As a result, MRK has agreed to pay PDLI a lump sum of $195 million in a settlement. In a statement, John McLaughlin, CEO at PDL BioPharma had the following to offer…




We are pleased to resolve this patent infringement lawsuit with Merck with a favorable monetary settlement to PDL as well as eliminating future litigation costs related to this matter for both parties.”

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on PDLI. In particular, we’re interested in how it intends on using the sum to be paid by MRK. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Want The News Faster?

Check out the CNA Finance News Desk to get the scoop before we have the time to write the full story!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









For sidebar:

0 119
aTyr Pharma Inc LIFE Stock News

aTyr Pharma Inc (NASDAQ: LIFE) is having an incredibly strong time in the market this morning, and for good reason. The company released positive clinical data, leading to excitement among investors and causing the stock to head for the sky. Of course, our partners at Trade Ideas were the first to alert us to the gains. At the moment (9:30), LIFE is trading at $3.15 per share after a gain of $0.10 per share or 3.28% thus far today.





LIFE Releases Positive Clinical Data

As mentioned above, aTyr Pharma is having a strong time in the market early on this morning after releasing positive clinical data. The results came from the Phase 1b/2 003 trial looking into the safety and potential activity of Resolaris(TM) as a treatment for patients with early onset facioscapulohumeral muscular dystrophy, also known as FSHD.




The data released showed that 63% of patients had increases from baseline in their Manual Muscle Test. This is a test that’s designed to assess muscle strength. The data showed a mean change from baseline of +3.8%. LIFE also said that 67% of patients had improvement in their Individualized Neuromuscular Quality of Life score. In a statement, Sanjay Skukla, MD, MS, Chief Medical officer at LIFE had the following to offer…

We are developing Resolaris, derived from a naturally occurring protein that we believe acts on a newly discovered immunological pathway to potentially treat patients with rare muscular dystrophies characterized by immune cell imbalance… These results are important as they reinforce previous clinical results (in adult FSHD and adult LGMD2B) with Resolaris in a younger patient population, with a potentially more aggressive progression of disease. We look forward to the advancement of Resolaris in the clinica in rare muscular dystrophies upon identification of a pharmacodynamic assay and the successful execution of our pipeline partnering efforts.”

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on aTyr Pharma (LIFE). In particular, we’re going to be following the continued development of Resolaris. Considering the positive results, this could turn out to be a huge thing for the company. Nonetheless, we’ll continue to follow the news closely and bring it to you as it breaks!

Want The News Faster?

Check out the CNA Finance News Desk to get the scoop before we have the time to write the full story!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









For sidebar:

[Image Courtesy of Wikimedia]

0 169
Biogen Inc BIIB Stock News

Biogen Inc (NASDAQ: BIIB) is having an incredibly strong time in the pre-market hours this morning, and for good reason. The company released data showing positive real-world experiences among patients using its leading MS therapies. As a result, investor excitement ensued and the stock found its way upward. As is almost always the case, our partners at Trade Ideas were the first to alert us to the movement. At the moment (8:32), LLY is trading at $275.31 per share after a gain of $2.37 per share or 0.87% thus far today.





BIIB Releases Positive Real-World Data

As mentioned above, Biogen is having a strong time in the pre-market hours after releasing positive real-world treatment data. The data came from the company’s leading MS therapies known as TECFIDERA(R) and TYSABRI(R). The company showed that when treated early in the course of the disease improved outcomes were seen in patients living with relapsed multiple sclerosis. According to the data, initiating the appropriate disease modifying therapy soon after diagnosis has been shown to slow the physical and cognitive decline associated with the disease, allowing these patients to stay active longer. In a statement, Kate Dawson, M.D., vice president of US Medical at BIIB had the following to offer…




The new real-world TECFIDERA and TYSABRI data presented at AAN emphasize the importance of effective treatment early in the course of one’s disease… Timely treatment with appropriate therapies can help mitigate damage caused by MS and delay long-term disability for people with the disease.”

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on BIIB. In particular, we’re interested in following TECFIDERA and TYSABRI to see if this positive data leads to expanded sales. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Want The News Faster?

Check out the CNA Finance News Desk to get the scoop before we have the time to write the full story!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









For sidebar:

[Image Courtesy of Wikimedia]

0 134
Eli Lilly And Co LLY Stock News

Eli Lilly And Co (NYSE: LLY) is having a strong time in the pre-market hours at the moment, and for good reason. The company released data with regard to a clinical stage treatment for breast cancer, showing improved overall survival rates. As a result, investor excitement ensued and the stock started to climb. Of course, our partners at Trade Ideas were the first to notify us of the gains. At the moment, LLY is trading at $83.26 per share after a gain of $1.37 per share or 1.67% thus far.





LLY Releases Positive Data




As mentioned above, Eli Lilly And Co is having an incredibly strong start to the day today in the pre-market hours as the result of news surrounding a late-stage clinical trial. The trial surrounds abemaciclib in combination with an aromatase inhibitor. According to the release, the combination treatment has improved overall survival rates in patients fighting advanced breast cancer. The company also expects that the treatment will be effective in treating other cancers such as lung cancer, brain metastases and pancreatic cancer.

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on LLY. In particular, we’ll be watching the ongoing work surrounding abemaciclib. Considering the overwhelmingly positive data surrounding the treatment, this could become a major revenue driver for the company moving forward. Nonetheless, we’ll continue to follow the news closely and bring it to you as it breaks!

Want The News Faster?

Check out the CNA Finance News Desk to get the scoop before we have the time to write the full story!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









For sidebar:

Thought Leader Discussions

Gevo, Inc. GEVO Stock News

0 4574
Gevo, Inc. (NASDAQ: GEVO) Before we get into this interview, I'd like to extend a special thanks to my friend Joey who both set up the...